Interesting question… The last forecast for Paxlovid availability didn’t look favorable for wide availability soon. I can’t offer conjecture on the second question now.
As an antiviral, paxlovid won’t affect testing unless it’s started before testing. We’ve already ruined the testing landscape, though. Positivity and absolute case numbers are nearly… or virtually meaningless.
What will happen to testing if
a) Paxlovid becomes much more widely available
And
b) We discover that Paxlovid is effective for a staggeringly large class of viruses
Interesting question… The last forecast for Paxlovid availability didn’t look favorable for wide availability soon. I can’t offer conjecture on the second question now.
Oh, not asking you to weigh in on whether either of those things are likely to happen. What if they do, at some undetermined time?
As an antiviral, paxlovid won’t affect testing unless it’s started before testing. We’ve already ruined the testing landscape, though. Positivity and absolute case numbers are nearly… or virtually meaningless.